Skip to main content

Table 1 Baseline characteristics of subjects with normal glucose tolerance, prediabetes, and type 2 diabetes (n = 6361)

From: FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China

  Normal glucose tolerance Prediabetes Type 2 diabetes p for trend
n 1553 3244 1564  
Males (%) 47.84 42.05 38.49 < 0.001
Age (years) 61.30 ± 3.91 61.83 ± 3.99 62.20 ± 4.04 < 0.001
Current smoker (%) 25.05 20.65 18.16 < 0.001
Current Drinker (%) 16.29 14.98 14.58 0.183
BMI (kg/m2) 23.97 ± 3.00 24.93 ± 3.23 25.98 ± 3.43 < 0.001
Waist circumference (cm) 82.81 ± 9.02 84.78 ± 9.29 87.60 ± 9.29 < 0.001
Systolic blood pressure (mmHg) 132.33 ± 15.60 135.56 ± 16.42 139.71 ± 17.19 < 0.001
Diastolic blood pressure (mmHg) 83.27 ± 8.88 84.46 ± 8.54 85.35 ± 8.50 < 0.001
Total cholesterol (mmol/L) 5.04 ± 0.95 5.28 ± 0.97 5.38 ± 1.06 < 0.001
Triglyceride (mmol/L)a 1.15 (0.81,1.62) 1.36 (0.96,1.97) 1.61 (1.14,2.40) < 0.001
HDL-C (mmol/L)a 1.34 (1.10,1.60) 1.30 (1.09,1.52) 1.25 (1.06,1.49) < 0.001
LDL-C (mmol/L) 2.97 ± 0.76 3.20 ± 0.80 3.25 ± 0.87 < 0.001
hsCRP (μg/mL)a 0.69 (0.37,1.39) 0.88 (0.46,1.75) 1.17 (0.59,2.46) < 0.001
Fasting plasma glucose (mmol/L) 5.48 ± 0.38 5.89 ± 0.49 7.73 ± 1.95 < 0.001
2-h plasma glucose (mmol/L) 6.19 ± 1.08 7.83 ± 1.69 14.39 ± 4.49 < 0.001
Fasting insulin (μU/mL)a 5.48 (4.01,7.64) 6.95 (4.95,9.76) 8.28 (5.75,12.15) < 0.001
HOMA-β (%)a 55.53 (40.88,76.38) 59.27 (40.98,84.30) 43.45 (27.50,66.92) < 0.001
HOMA-IRa 1.35 (0.96,1.89) 1.82 (1.29,2.57) 2.72 (1.87,4.16) < 0.001
HbA1c (mmol/mol) 34.58 ± 2.85 38.82 ± 3.64 50.29 ± 19.72 < 0.001
HbA1c (%) 5.31 ± 0.26 5.70 ± 0.33 6.75 ± 1.80 < 0.001
FGF21 (pg/mL)a 202.78 (120.33,308.17) 236.80 (144.88,362.09) 261.07 (167.62,398.87) < 0.001
Adiponectin (μg/mL)a 4.51 (3.34,6.00) 4.06 (3.08,5.40) 3.54 (2.70,4.72) < 0.001
FGF21/adiponectin ratio (pg/μg)a 45.37 (23.84,78.71) 58.52 (31.99,100.53) 73.92 (40.47,128.40) < 0.001
  1. Data are presented as mean ± SD or median (interquartile range)
  2. BMI: body mass index; FGF21: fibroblast growth factor 21; HDL-C: high-density lipoprotein cholesterol; HOMA: homeostasis model assessment; hsCRP: high-sensitivity C-reactive protein; IR: insulin resistance; LDL-C: low-density lipoprotein cholesterol
  3. aLoge-transformed before analysis